Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome

DOI: 10.1182/blood-2004-03-1209
Blood, 2004, 104, 2933-5.

#	Paper	IF	Citations
189	Organisation of neoplastic haematopathology services: a UK perspective. *Pathology*, **2005**, 37, 479-92	1.6	7
188	Diagnostic pathology of lymphoproliferative disorders. *Pathology*, **2005**, 37, 434-56	1.6	8
187	Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. *Blood*, **2005**, 106, 2491-7	2.2	186
186	T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. *Leukemia*, **2005**, 19, 652-8	10.7	309
185	FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. *Leukemia*, **2005**, 19, 1299-305	10.7	125
184	Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. **2005**, 18, 1377-84		106
183	Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 5138-43	11.5	431
182	Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma. *Expert Review of Molecular Diagnostics*, **2005**, 5, 397-408	3.8	1
181	Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. **2005**, 23, 6370-8		137
180	Insights into transcriptional regulation by FOXP3. **2006**, 11, 1607-19		12
179	Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. **2006**, 210, 163-71		36
178	FOXP3 ensembles in T-cell regulation. **2006**, 212, 99-113		65
177	Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice?. **2006**, 86, 742-7		16
176	AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. **2006**, 19, 438-46		17
175	Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. **2006**, 19, 9-16		40
174	Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. **2006**, 19, 1270-6		33
173	Identification of novel genes and transcription factors involved in spleen, thymus and immunological development and function. **2006**, 7, 101-12		9

172	Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. *Leukemia*, **2006**, 20, 1300-3	10.7	60
171	The FoxP subclass in Xenopus laevis development. **2006**, 216, 641-6		18
170	Gene arrays in lymphoma: Where will they fit in?. **2006**, 1, 129-36		3
169	Integrin signals, transcription factors, and monocyte differentiation. **2006**, 16, 146-52		35
168	t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. **2006**, 45, 164-8		46
167	Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. **2006**, 24, 2490-7		121
166	Prognostic biomarkers in diffuse large B-cell lymphoma. **2006**, 24, 995-1007		209
165	Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. **2007**, 25, 1350-6		268
164	A cytogenetically characterized, genome-anchored 10-Mb BAC set and CGH array for the domestic dog. **2007**, 98, 474-84		27
163	FOXP1: a potential therapeutic target in cancer. **2007**, 11, 955-65		117
162	Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. **2007**, 25, 1581-7		215
161	Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. **2007**, 25, 805-12		241
160	Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. *Biomarker Insights*, **2007**, 2, 117727190700200	3.5	4
159	Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. **2007**, 67, 1091-8		38
158	The emerging roles of forkhead box (Fox) proteins in cancer. **2007**, 7, 847-59		809
157	Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. *Leukemia*, **2007**, 21, 37-43	10.7	86
156	Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. **2007**, 51, 70-9		33
155	Mucosa-associated lymphoid tissue lymphoma: molecular pathogenesis and clinicopathological significance. **2007**, 57, 474-84		53

154	Molecular cloning, characterization, and developmental expression of foxp1 in zebrafish. **2007**, 217, 699-707		10
153	Marginal-zone lymphoma. **2007**, 63, 245-56		47
152	Pathway activation patterns in diffuse large B-cell lymphomas. *Leukemia*, **2008**, 22, 1746-54	10.7	33
151	The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. *Leukemia*, **2008**, 22, 1917-24	10.7	87
150	FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. **2008**, 21, 902-11		61
149	Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression. **2008**, 142, 562-70		11
148	Evaluation of intra- and interobserver agreement and its clinical significance for scoring bcl-2 immunohistochemical expression in diffuse large B-cell lymphoma. **2008**, 58, 596-600		10
147	Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. *Leukemia and Lymphoma*, **2008**, 49 Suppl 1, 43-51	1.9	93
146	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). *Blood*, **2008**, 112, 2248-60	2.2	165
145	A genome assembly-integrated dog 1 Mb BAC microarray: a cytogenetic resource for canine cancer studies and comparative genomic analysis. **2008**, 122, 110-21		30
144	Expression of Fox head protein 1 in human eutopic endometrium and endometriosis. **2008**, 15, 243-52		9
143	Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. *Clinical Cancer Research*, **2008**, 14, 3002-10	12.9	35
142	Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. *Blood*, **2008**, 111, 2816-24	2.2	75
141	Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. **2009**, 35, 547-57		32
140	Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). **2009**, 62, 128-38		79
139	Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. **2009**, 27, 5039-48		73
138	FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. **2009**, 26, 156-62		22
137	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. *International Journal of Oncology*, **2009**, 35, 961-71	4.4	11

136	Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. **2009**, 27, 5573-9		100
135	The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. **2009**, 5, e1000637		126
134	New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. **2009**, 62, 986-97		20
133	FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma. **2009**, 59, 354-8		4
132	Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. **2009**, 82, 364-72		28
131	Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma. **2009**, 33, 1699-702		23
130	Defining the molecular target of an antibody derived from nuclear extract of Jurkat cells using protein arrays. **2009**, 395, 119-24		4
129	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. *Clinical Cancer Research*, **2009**, 15, 5494-502	12.9	507
128	Ophthalmic lymphoma: epidemiology and pathogenesis. **2009**, 87 Thesis 1, 1-20		62
127	Diffuse aggressive B-cell lymphomas. **2009**, 16, 216-35		16
126	FOXP1 and BCL2 show similar immunoenzymatic pattern in bone marrow trephines of chronic lymphocytic leukemia patients. **2009**, 17, 500-4		4
125	Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma. **2009**, 68, 972-6		9
124	FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. **2010**, 57, 73-80		37
123	Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. **2010**, 149, 221-30		31
122	An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. **2010**, 38, 5336-50		47
121	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. *Leukemia and Lymphoma*, **2010** , 51, 2063-9	1.9	13
120	Local versus systemic treatment for primary cutaneous B-cell lymphoma. **2010**, 10 Suppl 2, S103-5		
119	Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. **2010**, 7, 336-46		101

118	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. **2010**, 28, 3360-5		440
117	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. *Leukemia and Lymphoma*, **2010**, 51, 199-212	1.9	77
116	Marginal zone B-cell lymphoma of the conjunctiva. **2010**, 5, 177-188		2
115	Prognostication of diffuse large B-cell lymphoma in the rituximab era. *Leukemia and Lymphoma*, **2011**, 52, 360-73	1.9	23
114	Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. *Tumor Biology*, **2011**, 32, 913-20	2.9	7
113	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Blood*, **2011**, 117, 4836-43	2.2	249
112	FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. **2011**, 90, 701-8		19
111	FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. **2011**, 2, 286-97		39
110	Solution structure and backbone dynamics of the DNA-binding domain of FOXP1: insight into its domain swapping and DNA binding. **2011**, 20, 908-24		26
109	BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. **2011**, 129, 70-7		21
108	MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Clinical Cancer Research*, **2011**, 17, 4125-35	12.9	110
107	Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. **2011**, 10, 396-405		147
106	Cumulative Epigenetic Abnormalities in Host Genes with Viral and Microbial Infection during Initiation and Progression of Malignant Lymphoma/Leukemia. **2011**, 3, 568-81		8
105	The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. **2012**, 25, 1439-45		5
104	Nutritional deficiencies and parasitic disease: lessons and advancements from rodent models. **2012** , 189, 97-103		5
103	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. *Leukemia*, **2012**, 26, 2103-13	10.7	251
102	Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases. **2012**, 154, 87-98.e1		31
101	Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specified. **2012**, 43, 1322-7		10

100	Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. **2012**, 29, 3352-9		12
99	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. *Leukemia and Lymphoma*, **2012**, 53, 1032-45	1.9	14
98	Non-Hodgkin Lymphoma. **2013**,		1
97	Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. **2013**, 63, 788-801		22
96	Cancer genetics and genomics of human FOX family genes. *Cancer Letters*, **2013**, 328, 198-206	9.9	251
95	Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China. **2013**, 115, 137-43		11
94	FOXP1 and estrogen signaling in breast cancer. **2013**, 93, 203-12		16
93	Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma. **2013**, 22, 736-44		12
92	Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. *Clinical Cancer Research*, **2013**, 19, 6686-95	12.9	91
91	MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. **2013**, 2013, 348212		22
90	Downregulation of FOXP1 is required during germinal center B-cell function. *Blood*, **2013**, 121, 4311-20	2.2	47
89	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. *Current Biomarker Findings*, **2013**, 17		1
88	Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1. *PLoS ONE*, **2014**, 9, e85851	3.7	16
87	Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. *PLoS ONE*, **2014**, 9, e98169	3.7	25
86	Rare Lymphomas. **2014**,		
85	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. *Acta Neuropathologica*, **2014**, 127, 175-88	14.3	47
84	miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. *Blood*, **2014**, 124, 84-95	2.2	106
83	Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. *Gastric Cancer*, **2014**, 17, 431-41	7.6	40

82	Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell. *Experimental and Molecular Pathology*, **2014**, 96, 1-8	4.4	10
81	Primary Cutaneous B-Cell Lymphomas. *Surgical Pathology Clinics*, **2014**, 7, 253-83	3.9	2
80	FOXP1 inhibits plasma cell differentiation. *Blood*, **2015**, 126, 2076-7	2.2	1
79	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. *American Journal of Surgical Pathology*, **2015**, 39, 1132-9	6.7	53
78	Best practices in diagnostic immunohistochemistry: workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma. *Archives of Pathology and Laboratory Medicine*, **2015**, 139, 338-50	5	21
77	FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma. *Science Signaling*, **2015**, 8, ra12	8.8	44
76	Abnormal expression of Forkhead Box J2 (FOXJ2) suppresses migration and invasion in extrahepatic cholangiocarcinoma and is associated with prognosis. *International Journal of Oncology*, **2015**, 46, 2449-58	4.4	13
75	Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. *Journal of Geriatric Oncology*, **2015**, 6, 141-52	3.6	47
74	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. *Leukemia*, **2015**, 29, 1004-17	10.7	171
73	Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?. *Expert Review of Molecular Diagnostics*, **2015**, 15, 471-90	3.8	15
72	Epithelial-mesenchymal transition-related factors in solid tumor and hematological malignancy. *Journal of the Chinese Medical Association*, **2015**, 78, 438-45	2.8	35
71	Diffuse large B-cell lymphoma and Burkitt lymphoma. *Diagnostic Histopathology*, **2015**, 21, 391-399	0.7	
70	Expression of FOXP1 and Colorectal Cancer Prognosis. *Laboratory Medicine*, **2015**, 46, 299-311	1.6	11
69	[A rare CD5-positive subgroup of diffuse large B-cell lymphoma - clinical, morphological and immunophenotypic features in Polish patients]. *Polish Journal of Pathology*, **2016**, 67, 235-243	0.9	2
68	Downregulation of FOXP1 Inhibits Cell Proliferation in Hepatocellular Carcinoma by Inducing G1/S Phase Cell Cycle Arrest. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	18
67	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. *Cancer Cytopathology*, **2016**, 124, 135-43	3.9	23
66	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features. *American Journal of Transplantation*, **2016**, 16, 414-25	8.7	51
65	The prognostic role and reduced expression of FOXJ2 in human hepatocellular carcinoma. *Molecular Medicine Reports*, **2016**, 14, 254-62	2.9	5

64	Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. *Scientific Reports*, **2016**, 6, 30437	4.9	13
63	Helicobacter pylori Infection and MALT Lymphoma. **2016**, 423-441		1
62	Helicobacter pylori Research. **2016**,		3
61	The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. *Blood*, **2016**, 127, 1438-48	2.2	45
60	Release the hounds: virotherapy with immunotherapy. *Blood*, **2016**, 127, 1381-3	2.2	4
59	S1PR2 deficiency in DLBCL: a FOXy connection. *Blood*, **2016**, 127, 1380-1	2.2	2
58	The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. *Pathology and Oncology Research*, **2016**, 22, 567-77	2.6	7
57	A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma. *Cancer Letters*, **2016**, 374, 1-11	9.9	41
56	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. *Experimental Hematology*, **2016**, 44, 238-46.e2	3.1	39
55	Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists. *Pathology*, **2016**, 48, 5-16	1.6	7
54	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. *Leukemia*, **2016**, 30, 361-72	10.7	41
53	Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. *Molecular Cancer Therapeutics*, **2017**, 16, 1246-1256	6.1	38
52	The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas. *Tumor Biology*, **2017**, 39, 1010428317699129	2.9	7
51	The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells. *Haematologica*, **2017**, 102, 573-583	6.6	8
50	Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma. *Blood Cancer Journal*, **2017**, 7, e596	7	11
49	FOXP1 is a regulator of quiescence in healthy human CD4 T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. *European Journal of Immunology*, **2017**, 47, 168-179	6.1	18
48	Transformation of marginal zone lymphoma (and association with other lymphomas). *Best Practice and Research in Clinical Haematology*, **2017**, 30, 131-138	4.2	17
47	BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. *Veterinary and Comparative Oncology*, **2017**, 15, 1269-1279	2.5	10

46	The significance of FOXP1 in diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2017**, 58, 1037-1051	11	28
45	Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 3120-3125	11.5	19
44	The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. *Blood*, **2018**, 131, 2235-2246	2.2	28
43	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. *Blood Reviews*, **2018**, 32, 400-415	11.1	28
42	downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. *Blood*, **2018**, 132, 2389-2400	2.2	26
41	MiR-92a regulates oral squamous cell carcinoma (OSCC) cell growth by targeting FOXP1 expression. *Biomedicine and Pharmacotherapy*, **2018**, 104, 77-86	7.5	14
40	MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. *Leukemia*, **2019**, 33, 403-414	10.7	30
39	Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study. *Surgical and Experimental Pathology*, **2019**, 2,	1.6	
38	Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. *Scientific Reports*, **2019**, 9, 10495	4.9	9
37	Novel markers in pediatric-type follicular lymphoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 771-779	5.1	15
36	MALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric Tumor Development. *Current Topics in Microbiology and Immunology*, **2019**, 421, 77-106	3.3	6
35	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. *Surgical Pathology Clinics*, **2019**, 12, 699-707	3.9	9
34	Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression. *Molecular Cancer*, **2019**, 18, 180	42.1	25
33	Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 503-514	4.9	3
32	Integrative analyses of single-cell transcriptome and regulome using MAESTRO. *Genome Biology*, **2020**, 21, 198	18.3	38
31	Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. *Frontiers in Oncology*, **2020**, 10, 506	5.3	12
30	CircRNA_OTUD7A upregulates FOXP1 expression to facilitate the progression of diffuse large B-cell lymphoma via acting as a sponge of miR-431-5p. *Genes and Genomics*, **2021**, 43, 653-667	2.1	4
29	Diffuse Large B-Cell Lymphomas in Older Adults. **2020**, 583-612		1

28	Ocular and Adnexal Lymphoma: Molecular Pathology. *Essentials in Ophthalmology*, **2014**, 25-46	0.2	2
27	Nodular Lymphocyte-Predominant Type of Hodgkin Lymphoma. **2011**, 436-453		1
26	Genome-wide transcriptomic analysis of intestinal tissue to assess the impact of nutrition and a secondary nematode challenge in lactating rats. *PLoS ONE*, **2011**, 6, e20771	3.7	15
25	CASC21, a FOXP1 induced long non-coding RNA, promotes colorectal cancer growth by regulating CDK6. *Aging*, **2020**, 12, 12086-12106	5.6	7
24	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. *Oncotarget*, **2016**, 7, 52940-52956	3.3	13
23	Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience. *Croatian Medical Journal*, **2008**, 49, 618-24	1.6	4
22	Hematologic malignancies: correlation between morphology, phenotype,. **2008**, 125-242		
21	Differential diagnosis chromosomal/molecular changes. **2008**, 542-566		
20	Marginal Zone B-Cell Lymphoma. *Molecular Pathology Library*, **2010**, 221-231		
19	Marginal zone lymphomas. **2010**, 499-512		
18	Primary Cutaneous B-Cell Lymphoma. **2011**, 306-318		
17	Prognostic Factors in B-Cell Lymphomas. **2013**, 101-139		
16	Signaling Pathways in Rare Lymphomas. **2014**, 71-95		
15	Cytogenetics. **2014**, 17-60		
14	Science Signaling Podcast: 3 February 2015. *Science Signaling*, **2015**, 8,	8.8	
13	Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. *Medicinski Arhiv = Medical Archives = Archives De Medecine*, **2016**, 70, 342-347	1.2	2
12	Diffuse Large B-Cell Lymphomas in Older Adults. **2018**, 1-31		
11	Whole-exome Sequencing Reveals Genetic Underpinnings of Tongue Carcinoma in Chinese Population. **2020**, 1-9		

10	Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas. *Biomarker Insights*, **2007**, 2, 403-17	3.5	
9	MiR-206 is down-regulated and suppresses cell proliferation by targeting FOXP1 in brain gliomas. *International Journal of Clinical and Experimental Pathology*, **2018**, 11, 3405-3415	1.4	4
8	Mature Lymphoid Neoplasms. **2020**, 245-282		
7	Comprehensive Analysis of Prognostic and immune infiltrates for FOXPs Transcription Factors in Human Breast Cancer. *Scientific Reports*, **2022**, 12,	4.9	0
6	Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma. *Clinical Cancer Research*, **2005**, 11, 1065-1072	12.9	36
5	Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion. 13,		1
4	FOXP1 and FOXO3a Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas. Publish Ahead of Print,		0
3	Genetics of Transformed Follicular Lymphoma. **2022**, 3, 615-633		0
2	Pediatric-type follicular lymphoma: a short review. **2022**, 11,		0
1	FOXP1 inhibits pancreatic cancer growth by transcriptionally regulating IRF1 expression. **2023**, 18, e0280794		0